Toy Medical Co., Ltd.
Human clinical study confirms that intake of alginate suppresses dietary salt absorption
Toy Medical Co., Ltd. (Headquarters: Kamimashiki-gun, Kumamoto Prefecture; President: Hidenori Takeshita) has confirmed in human clinical trials that intake of alginate suppresses the absorption of salt (sodium) from meals. A paper on this result was published in “Pharmacology and Therapy (2022, Vol. 50, No. 10, 1829-1836)”. Inhibitory effect of sodium absorption by intake of
―A placebo-controlled, randomized, double-blind, crossover study― Authors: Takamasa Masuda1, Akiko Okamura1, Kosei Nishikawa1, Hirohito Nishikawa1, Junichi Yatabe2, Yuya Hayashi3, Hidenori Takeshita3 1Healthcare Systems Co., Ltd., 2Telemedis Association, 3Toy Medical Co., Ltd. Source: Pharmacology and Therapeutics, Volume 50, Issue 10, 1829-1836 (2022). Publisher: Life Science Publishing
For details, please check the Toy Medical Co., Ltd. website. http://www.toymedical.jp/news/
Company name: Toy Medical Co., Ltd.
Business description: Development and sales of medical equipment, health foods, and beauty products
Date of establishment: October 9, 2013
Location: 750-1 Toyoaki, Mifune-cho, Kamimashiki-gun, Kumamoto Prefecture Representative: Hidenori Takeshita
Capital: 100 million yen
Details about this release: